Biosplice announces clinical data from Phase 2b lorecivivint trial
Category: #health  By Pankaj Singh  Date: 2021-04-27
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Biosplice announces clinical data from Phase 2b lorecivivint trial

Biosplice Therapeutics, Inc., a biotech company, has recently announced the publication of its successful Phase 2b clinical trial data of its knee OA drug candidate, lorecivivint, in Osteoarthritis & Cartilage. In this clinical trial that lasted for 24 weeks, the groundbreaking drug candidate met the primary endpoints of Pain NRS at both 12- as well as 24-week timepoints.

Yusuf Yazici, MD, Chief Medical Officer of Biosplice Therapeutics, has reportedly cited that healthcare professionals require an approach to treat knee osteoarthritis that provides durable pain relief, high functionality, and safety. The company has also been lending a major focus on the delivery of an efficient knee osteoarthritis treatment with increased safety and efficacy. Its local and intra-articular injection is anticipated to offer a much-needed disease-modifying treatment option for patients and physicians alike.

In the current scenario, Biosplice is conducting two Phase 3 clinical trials for lorecivivint, i.e. STRIDES-1 & STRIDES-X-ray, which are expected to be completed in the 2nd half of 2021. These Phase 3 clinical trials (NCT04385303 & NCT03928184) will further evaluate the significant impact of lorecivivint in treating knee osteoarthritis pain, structure, & function, and have been modeled after the biotech company’s successful Phase 2b trial from the standpoint of the primary endpoints of the daily score at 3 months.

According to Biosplice Therapeutics’ SVP of Clinical Affairs, Mark Fineman, the company has measured knee pain as the primary endpoints at 3 months during the Phase 3 trials, while further benefitting in statistical power from the enrollment of nearly twice the number of the subjects per arm. In addition, it is also measuring the structural & functional improvements as the key secondary endpoints as well as evidence of disease modification.

As per the trial data, lorecivivint, a small-molecule inhibitor of the Wnt pathway, showed statistically significant and clinically meaningful improvements in function and pain as compared to its placebo among patients with knee osteoarthritis.

Source credit:

https://www.globenewswire.com/news-release/2021/04/26/2216940/0/en/Biosplice-Publishes-Successful-Clinical-Trial-in-Knee-Osteoarthritis.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

By Pankaj Singh

Well-known medical practice management organization, Medical Group Management Association (MGMA) has reportedly joined forces with WhiteSpace Health to release a new medical group analytics tool, MGMA DataDiscovery. Th...

Santex acquires U.S. online retailer Parentgiving for market expansion

Santex acquires U.S. online retailer Parentgiving for market expansion

By Pankaj Singh

Italy-based personal care and incontinence product manufacturer Santex SPA has reportedly acquired Parentgiving Inc., America’s top-rated e-commerce retailer of geriatric care products.

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...